Martine A. Rothblatt, serving as both Chairperson and Chief Executive Officer of United Therapeutics Corp. (NASDAQ:UTHR), executed a sale of 9,500 shares of the company's common stock on June 23, 2026. The transaction resulted in proceeds totaling $5,167,570. These shares were sold within a price range of $539.62 to $546.55 per share. The activity was carried out under the framework of a pre-arranged 10b5-1 trading plan that Rothblatt established on November 7, 2025. This specific plan outlines the procedures for exercising stock options and the subsequent disposition of the shares acquired through that exercise.
The timing of this sale coincides with a substantial 88% increase in United Therapeutics' share price over the preceding twelve months. As of the reporting date, the stock was trading at $549.90, assigning the company a market capitalization of $23.28 billion. An analysis by InvestingPro indicates that the current valuation places UTHR among companies deemed overvalued relative to their calculated Fair Value. Prior to the sale, Rothblatt had acquired the 9,500 shares through the exercise of stock options. These options were exercised at a strike price of $135.42 per share, representing a total exercise value of $1,286,489.
Following the transaction, Rothblatt's direct ownership in United Therapeutics stands at 40,513 shares. Her broader beneficial ownership extends through indirect holdings, including 166 shares held by a spouse. Furthermore, she maintains significant interests across multiple family trusts: 324,443 shares in trusts where she shares investment power and is a beneficiary, 249,108 shares in trusts where her spouse acts as sole trustee and beneficiary or co-trustee with revocation power, 45,596 shares in trusts where her spouse shares investment power, and 8,902 shares in trusts where she is sole trustee and beneficiary or co-trustee with revocation power. Additionally, Rothblatt holds derivative securities, including 134,718 stock options held directly. Indirectly, through a family trust where she shares investment power and is a beneficiary alongside immediate family members, she holds an additional 349,192 stock options. These options carry an exercise price of $135.42 and are scheduled to expire on March 15, 2027.
United Therapeutics continues to demonstrate robust financial metrics, maintaining gross profit margins of 87%, which underscores strong pricing power for its therapeutic products. The stock showed resilience in recent trading, closing at $549.90, up $5.68 or 1.04%, and trading at $557.94 after hours, up $8.04 or 1.46%. The company's strategic initiatives and financial performance have drawn attention from market analysts. United Therapeutics recently announced that its TETON-1 phase 3 study of nebulized Tyvaso for idiopathic pulmonary fibrosis successfully met its primary endpoint. Results published in the New England Journal of Medicine indicated that Tyvaso preserved lung function and significantly reduced the risk of clinical worsening events.
Despite positive clinical developments, the company reported first-quarter revenue of $781.5 million, which fell short of the consensus estimate of $797.4 million. Revenue from Tyvaso specifically was $457.5 million, below the expected $478.6 million. Net income for the quarter was reported at $274.9 million, compared to the consensus of $320.5 million. In response to these earnings, BTIG reiterated a Neutral rating on the stock. Conversely, TD Cowen reiterated a Buy rating, maintaining a price target of $675.00. United Therapeutics is also collaborating with Varda Space Industries to explore microgravity-based pharmaceutical processing for rare pulmonary disease treatments. This partnership aims to leverage the unique conditions of microgravity to enhance the stability and delivery of therapeutic compounds.